BMS/Innate drug fails to impress in AML trial
An investigational drug being developed by Innate Pharma in partnership with Bristol-Myers Squibb for elderly patients with acute myeloid leukaemia (AML) has failed to hit key targets in a Phase II trial.
Read More
